Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Research Associate, MRNA Process Development

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Jan 24, 2022

View more

Job Details

Why Join Intellia? 

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. 

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done. 

We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.   

How you will Achieve More with Intellia:

 In this Senior Research Associate role, you will be responsible for building tools required for the development of novel mRNA synthetic and purification processes in support of our lead and future in vivo gene editing therapeutic candidates. To this end, you will leverage your biochemistry experiences and purification process to fully develop efficient tools in the downstream purification processes required for Nucleic Acids.

  • You will help advance our gene editing candidates such as NTLA2001 into a commercial process

  • Explore the broad spectrum of purification tools to develop and scale up next generation nucleic acid therapeutics in support of Intellia’s platform technologies

  • Design and perform process characterization studies (with some guidance), e.g. enzymatic reactions, Tangential Flow filtration (TFF, UF/DF), using DOE approaches and analyze experimental data

  • Investigate new purification technologies, e.g. chromatography and filtration, to enhance product purity and process robustness

  • Provide high quality Electronic Lab Notebook (ELN) documentations. Author and review technical reports

  • Assist in technology transfers to CDMOs

  • Operate and maintain multiple laboratory instruments. Assist in maintaining general laboratory functionality and supplies

 

About You:

 As an ideal candidate for this role, you have worked in process development or manufacturing science teams to develop late-stage manufacturing processes for large molecule drug substances or cell therapeutics. Additionally, you have experience working with oligonucleotides (RNAs/ DNAs) and understand basic biochemistry principles and analytical techniques necessary to characterize the product and impurities. Most importantly, if you have an enthusiast curiosity to develop mRNA processes and learn about the future of medicine in gene editing, then we encourage you to apply! Additional role requirements include:

  • Proven record of successfully planning and executing lab experiments and projects.

  • Lab experience in purification of DNA/RNA and/or proteins using TFF and/or column chromatography.

  • Ability to multitask and handle a diverse array of challenges within a dynamic team environment

  • Bachelor’s or Masters degree in Biochemistry, Biochemical Engineering, Chemical Engineering, or related field with 2+ years work experience

Meet your future team:

The Nucleic Acid Process Sciences team is a fun and energetic team of scientists focused on the internal development of nucleic acid therapeutics to create the curative gene editing technologies of the future. As a team, we drive the late-stage development of Intellia’s mRNA DS for Intellia’s lead programs. Furthermore, we are responsible for the development of enzymatic process and characterization tools to build a wide range of nucleic acid modalities for Intellia’s next generation platform technologies. We have an interesting and diverse background and set of experiences reflecting the breadth and depth of our responsibilities, and we look forward to meeting and welcoming onboard the next member of the team!

#LI-LK1

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert